BRAFV600E detection in melanoma is highly improved by COLD-PCR

Clinica Chimica Acta

Volumn 412, Issue 11-12, 2011, Pages 901-905

  Pinzani, Pamela ^a   Santucci, Claudio ^a   Mancini, Irene ^a   Simi, Lisa ^a   Salvianti, Francesca ^a   Pratesi, Nicola ^a   Massi, Daniela ^a   De Giorgi, Vincenzo ^a   Pazzagli, Mario ^a   Orlando, Claudio ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

BRAFV600E; COLD PCR; Melanoma; Somatic mutation

Indexed keywords

B RAF KINASE; PARAFFIN;

ADULT; AGED; ALLELE; ARTICLE; CANCER TISSUE; CONTROLLED STUDY; ENZYME DENATURATION; FEMALE; GENE AMPLIFICATION; GENETIC VARIABILITY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MALE; MELANOMA; MUTATIONAL ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PYROSEQUENCING; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS; SOMATIC MUTATION; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; DNA MUTATIONAL ANALYSIS; FEMALE; FORMALDEHYDE; HUMANS; MALE; MELANOMA; MIDDLE AGED; MUTATION; NUCLEIC ACID DENATURATION; PARAFFIN EMBEDDING; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS B-RAF; TRANSITION TEMPERATURE;

EID: 79955008740     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2011.01.014     Document Type: Article

References (22)

1. Futreal P.A., Coin L., Marshall M., et al. A census of human cancer genes. Nat Rev Cancer 2004, 4:177-183.
2. Greenman C., Stephens P., Smith R., et al. Patterns of somatic mutation in human cancer genomes. Nature 2007, 446:153-158.
3. Shinozaki M., O'Day S.J., Kitago M., et al. Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy. Clin Cancer Res 2007, 13:2068-2074.
4. Chang D.Z., Panageas K.S., Osman I., Polsky D., Busam K., Chapman P.B. Clinical significance of BRAF mutations in metastatic melanoma. J Transl Med 2004, 2:46.
5. Chudnovsky Y., Khavari P.A., Adams A.E. Melanoma genetics and the development of rational therapeutics. J Clin Invest 2005, 115:813-824.
6. Lea A., Allingham-Hawkins D., Levine S. BRAF p.Val600Glu (V600E) Testing for assessment of treatment options in metastatic colorectal cancer. PLoS Curr 2010, 2:RRN1187.
7. Davies H., Bignell G.R., Cox C., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
8. Nikiforova M.N., Nikiforov Y.E. Molecular diagnostics and predictors in thyroid cancer. Thyroid 2009, 19:1351-1361.
9. Liu W., Kelly J.W., Trivett M., et al. Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma. J Invest Dermatol 2007, 127:900-905.
10. Wellbrock C., Hurlstone A. BRAF as therapeutic target in melanoma. Biochem Pharmacol 2010, 80:561-567.
11. Karasarides M., Chiloeches A., Hayward R., et al. B-RAF is a therapeutic target in melanoma. Oncogene 2004, 23:6292-6298.
12. Flaherty K., Puzanov I., Sosman J. Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol 2009, 27(15s). (abstr 9000).
13. Halaban R., Zhang W., Bacchiocchi A., et al. PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res 2010, 23:190-200.
14. Li J., Wang L., Mamon H., Kulke M.H., Berbeco R., Makrigiorgos G.M. Replacing PCR with COLD-PCR enriches variant DNA sequences and redefines the sensitivity of genetic testing. Nat Med 2008, 14:579-584.
15. Lehmann U., Glöckner S., Kleeberger W., von Wasielewski H.F., H.Kreipe Detection of gene amplification in archival breast cancer specimens by laser-assisted microdissection and quantitative real-time polymerase chain reaction. Am J Pathol 2000, 156:1855-1864.
16. Spittle C., Ward M.R., Nathanson K.L., et al. Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma. J Mol Diagn 2007, 9:464-471.
17. Simi L., Pratesi N., Vignoli M., et al. High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. Am J Clin Pathol 2008, 130:247-253.
18. Friedlander P., Hodi F.S. Advances in targeted therapy for melanoma. Clin Adv Hematol Oncol 2010, 8:619-635.
19. Arkenau H.T., Kefford R., Long G.V. Targeting BRAF for patients with melanoma. Br J Cancer 2010, doi:10.1038/sj.bjc.6606030.
20. Mancini I., Santucci C., Sestini R., et al. The use of COLD-PCR and high-resolution melting analysis improves the limit of detection of KRAS and BRAF mutations in colorectal cancer. J Mol Diagn 2010, 12:705-711.
21. Zuo Z., Chen S.S., Chandra P.K., et al. Application of COLD-PCR for improved detection of KRAS mutations in clinical samples. Mod Pathol 2009, 22:1023-1031.
22. Li J., Milbury C.A., Li C., Makrigiorgos G.M. Two-round coamplification at lower denaturation temperature-PCR (COLD-PCR)-based sanger sequencing identifies a novel spectrum of low-level mutations in lung adenocarcinoma. Hum Mutat 2009, 30:1583-1590.